Shots:
- Genmab has reported P-III (EPCORE FL-1) trial data assessing epcoritamab (SC) + rituximab & lenalidomide (R2) vs R2 alone for the treatment of adult patients with r/r follicular lymphoma
- The trial met dual primary endpoints with improved ORR and PFS, reducing risk of progression or death by 79%; interim data will be submitted to support regulatory submission & for ASH presentation
- Additionally, in July 2025, the FDA accepted sBLA under priority review for epcoritamab + R2 after ≥1 prior therapy, based on interim data showing significant ORR (95.7%) & PFS benefits (PDUFA: Nov 30, 2025)
Ref: Businesswire | Image: Genmab |Press Release
Related News:- Genmab and Pfizer Secure the EC’s Approval for Tivdak (Tisotumab Vedotin) for Recurrent or Metastatic Cervical Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
